<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01566604</url>
  </required_header>
  <id_info>
    <org_study_id>CNVA237A2309</org_study_id>
    <nct_id>NCT01566604</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease</brief_title>
  <acronym>GLOW7</acronym>
  <official_title>A 26-week Treatment, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of NVA237 (50 µg o.d.) in Patients With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will assess of the efficacy and safety of a once-daily, 50µg inhalation of NVA237
      in moderate to severe chronic obstructive pulmonary disease (COPD) patients over 26 weeks
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trough Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Baseline FEV1 was defined as the average of the -45 min and -15 min FEV1 values taken on day 1 prior to the first dose of study medication. Trough FEV1 was defined as the mean of the post-dose 23 h 15 min and the 23 h 45 min FEV1 values. FEV1 was measured using central spirometry according to ATS/ERS standardization. Trough FEV1 was analyzed using a MIXED model for the full analysis set population. The model contained treatment as a fixed effect with the baseline FEV1 measurement, FEV1 prior to inhalation of short acting bronchodilator, FEV1 45 min post inhalation of short acting bronchodilator and baseline inhaled corticosteroids (ICS) use as covariates.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transition Dyspnea Index (TDI) Score</measure>
    <time_frame>Baseline, week 12, week 26</time_frame>
    <description>Dyspnea was measured at baseline using the Baseline Dyspnea Index (BDI) and during the treatment period using the TDI, which captures changes from baseline. The BDI and TDI each have three domains: functional impairment, magnitude of task and magnitude of effort, and each domain scored from -3 (major deterioration) to +3 (major improvement), giving an overall score of -9 to +9. A negative score indicates deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Rescue Medication Use (Number of Puffs)</measure>
    <time_frame>Baseline, 26 weeks</time_frame>
    <description>The participant recorded the rescue medication taken in an electronic diary between visits and in the spirometry device during study visits. Daytime and nighttime rescue medication use (number of puffs) over 26 weeks was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24h Trough FEV1</measure>
    <time_frame>Day 1, Week 26</time_frame>
    <description>Trough FEV1 was defined as the mean of the post-dose 23 h 15 min and the 23 h 45 min FEV1 values. This was measured using central spirometry according to ATS/ERS standardization. This was analyzed using the same MIXED model as specified for the primary analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 and Forced Vital Capacity (FVC)</measure>
    <time_frame>Day 1 at 5, 15, 30 minutes (min) and 1 hour (h) post dose; days 2, 86, 184 at 23 (h) 15 min and 23 h 45 min post dose; days 29, 85, 183 at -45 and -15 min pre-dose and 5, 15, and 30 min post dose</time_frame>
    <description>FEV1 and FVC were measured using central spirometry according to ATS/ERS standardization. Both were analyzed using the same MIXED model as specified for the primary analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1</measure>
    <time_frame>Day 1, week 12, week 26</time_frame>
    <description>Peak FEV1 was defined as the maximum FEV1 0-4 h post-dose. Peak Fev1 was measured at 45min and 15min pre-dose and up to 4h post dose at day 1, week 12 and week 26, using central spirometry according to ATS/ERS standardization. It was analyzed using the same MIXED model as specified for the primary analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standardized FEV1 Area Under the Curve (AUC(5 Min-4 h)) Post-dose</measure>
    <time_frame>Day 1, week 12, week 26</time_frame>
    <description>The standardized (with respect to time) AUC for FEV1 was calculated between 5 min and 4h post morning dose at day 1, week 12 and week 26. The AUC (5 min-4 h) for FEV1 at each visit was analyzed using the same MIXED model as specified for the primary analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Chronic Obstructive Pulmonary Disease (COPD) Symptoms (Cough, Wheezing, Shortness of Breath, Sputum Volume, Sputum Color and Night Time Awakenings)</measure>
    <time_frame>Baseline, 26 weeks</time_frame>
    <description>In an electronic diary, the participant responded to 6 questions twice daily to report on the degree of symptoms over the past 12 hours of the morning and evening. The questions covered the participant's degree of overall symptoms, and degrees of individual symptoms of coughing, wheezing, amount of sputum, color of sputum and breathlessness. Each question scored from 0 to 3 where 0 represented no symptom present and 3 represented the worst degree of that symptom. A negative change in symptom score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Moderate or Severe COPD Exacerbation</measure>
    <time_frame>26 weeks</time_frame>
    <description>A COPD exacerbation was defined as a worsening of the following two or more major symptoms for at least 2 consecutive days:1) dyspnea; 2) sputum volume; 3) sputum purulence; or defined as a worsening of any 1 major symptom together with an increase in any 1 of the following minor symptoms for at least 2 consecutive days: 1) sore throat; 2) colds (nasal discharge and/or nasal congestion); 3) fever without other cause; 4) cough; 5) wheeze. COPD exacerbations were recorded in the patient diary and other source documents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Moderate and Severe COPD Exacerbations</measure>
    <time_frame>26 weeks</time_frame>
    <description>COPD exacerbations were recorded in the patient diary and other source documents. The rate of COPD exacerbations during the 26 week treatment period was analyzed using a generalized linear model assuming a negative binomial distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Total Score of the St George's Respiratory Questionnaire (SGRQ)</measure>
    <time_frame>Week 12, week 26</time_frame>
    <description>SGRQ is a health related quality of life questionnaire consisting of 51 items in three components: symptoms, activity and impacts. The lowest possible score is zero and the highest possible score is 100. Higher scores correspond to greater impairment in quality of life. The health-related quality of life was measured using SGRQ. It was completed by the participant at the investigators site.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">460</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>NVA237</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NVA237 50 µg once daily delivered via a single dose dry powder inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily delivered via a single dose dry powder inhaler</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVA237</intervention_name>
    <description>Delivered via a single dose dry powder inhaler</description>
    <arm_group_label>NVA237</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Delivered via a single dose dry powder inhaler</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female adults aged ≥40 years, who have signed an Informed Consent Form prior
             to initiation of any study-related procedure

          -  With moderate to severe stable COPD (Stage II or Stage III).

          -  Current or ex-smokers who have a smoking history of at least 10 pack years (Ten pack-
             years are defined as 20 cigarettes a day for 10 years, or 10 cigarettes a day for 20
             years).

          -  Post-bronchodilator FEV1 ≥30% and &lt; 80% of the predicted normal, and
             post-bronchodilator FEV1/FVC &lt; 0.7 at Visit 2 (Day -14) (post means: record FEV1 and
             FVC 45 min after administering ipratropium).

          -  Symptomatic patients, according to daily electronic diary data between Visit 2 (Day
             -14) and Visit 3 (Day 1), with a total score of 1 or more on at least 4 of the last 7
             days prior to Visit 3

        Exclusion Criteria:

          -  With a history of malignancy of any organ system (including lung cancer), treated or
             untreated, within the past 5 years whether or not there is evidence of local
             recurrence or metastases, with the exception of localized basal cell carcinoma of the
             skin.

          -  Patients with any history of asthma indicated by (but not limited to) a blood
             eosinophil count &gt; 600/mm3 (at Visit 2) or onset of symptoms prior to age 40 years.
             Patients without asthma but who have a blood eosinophil count &gt;600/mm3 at Visit 2 are
             excluded.

          -  Patients with concomitant pulmonary disease, e.g. pulmonary tuberculosis (unless
             confirmed by imaging to be no longer active) or clinically significant bronchiectasis,
             sarcoidosis and interstitial lung disorder.

          -  Patients with lung lobectomy or lung volume reduction or lung transplantation.

          -  Patients with known history and diagnosis of α-1 antitrypsin deficiency.

          -  Patients who have had a COPD exacerbation that required treatment with antibiotics,
             systemic steroids (oral or intravenous) or hospitalization in the 6 weeks prior to
             Visit 1 Patients who have had a respiratory tract infection within 6 weeks prior to
             Visit 1.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100023</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Changsha City</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shengyang</city>
        <state>Liaoning</state>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chongqing</city>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chongqing</city>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chongqing</city>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guang zhou</city>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dehli</city>
        <state>New Delhi</state>
        <zip>110063</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coimbatore</city>
        <state>Tamil Nadu</state>
        <zip>641 045.</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Daejeon</city>
        <zip>301-804</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Incheon</city>
        <zip>403-010</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>130-709</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>150-713</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bulacan</city>
        <zip>3020</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Las Pinas</city>
        <zip>1740</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1100</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Philippines</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2012</study_first_submitted>
  <study_first_submitted_qc>March 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2012</study_first_posted>
  <results_first_submitted>June 3, 2014</results_first_submitted>
  <results_first_submitted_qc>July 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 8, 2014</results_first_posted>
  <last_update_submitted>July 16, 2014</last_update_submitted>
  <last_update_submitted_qc>July 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic obstructive pulmonary disease (COPD)</keyword>
  <keyword>NVA237</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycopyrrolate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were randomized in a 2: 1 ration to NVA237 and Placebo, respectively.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>NVA237</title>
          <description>NVA237 50 µg once daily delivered via a single dose dry powder inhaler</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo once daily delivered via a single dose dry powder inhaler</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="306"/>
                <participants group_id="P2" count="154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set</title>
              <participants_list>
                <participants group_id="P1" count="305"/>
                <participants group_id="P2" count="154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set (FAS)</title>
              <participants_list>
                <participants group_id="P1" count="305"/>
                <participants group_id="P2" count="154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>FAS, Serial Spirometry Subgroup</title>
              <participants_list>
                <participants group_id="P1" count="134"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="282"/>
                <participants group_id="P2" count="143"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Patient's inability to use the device</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal laboratory value</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NVA237</title>
          <description>NVA237 50 µg once daily delivered via a single dose dry powder inhaler</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo once daily delivered via a single dose dry powder inhaler</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="305"/>
            <count group_id="B2" value="154"/>
            <count group_id="B3" value="459"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.6" spread="7.84"/>
                    <measurement group_id="B2" value="65.0" spread="8.29"/>
                    <measurement group_id="B3" value="64.7" spread="7.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="294"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B3" value="439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Trough Forced Expiratory Volume in One Second (FEV1)</title>
        <description>Baseline FEV1 was defined as the average of the -45 min and -15 min FEV1 values taken on day 1 prior to the first dose of study medication. Trough FEV1 was defined as the mean of the post-dose 23 h 15 min and the 23 h 45 min FEV1 values. FEV1 was measured using central spirometry according to ATS/ERS standardization. Trough FEV1 was analyzed using a MIXED model for the full analysis set population. The model contained treatment as a fixed effect with the baseline FEV1 measurement, FEV1 prior to inhalation of short acting bronchodilator, FEV1 45 min post inhalation of short acting bronchodilator and baseline inhaled corticosteroids (ICS) use as covariates.</description>
        <time_frame>12 weeks</time_frame>
        <population>The number of participants considered for the analysis was from the full analysis set (randomized participants who received at least one dose of study medication). However, participants analyzed had both baseline and week 12 values.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237</title>
            <description>NVA237 50 µg once daily delivered via a single dose dry powder inhaler</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily delivered via a single dose dry powder inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Expiratory Volume in One Second (FEV1)</title>
          <description>Baseline FEV1 was defined as the average of the -45 min and -15 min FEV1 values taken on day 1 prior to the first dose of study medication. Trough FEV1 was defined as the mean of the post-dose 23 h 15 min and the 23 h 45 min FEV1 values. FEV1 was measured using central spirometry according to ATS/ERS standardization. Trough FEV1 was analyzed using a MIXED model for the full analysis set population. The model contained treatment as a fixed effect with the baseline FEV1 measurement, FEV1 prior to inhalation of short acting bronchodilator, FEV1 45 min post inhalation of short acting bronchodilator and baseline inhaled corticosteroids (ICS) use as covariates.</description>
          <population>The number of participants considered for the analysis was from the full analysis set (randomized participants who received at least one dose of study medication). However, participants analyzed had both baseline and week 12 values.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.204" spread="0.0135"/>
                    <measurement group_id="O2" value="1.063" spread="0.0160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transition Dyspnea Index (TDI) Score</title>
        <description>Dyspnea was measured at baseline using the Baseline Dyspnea Index (BDI) and during the treatment period using the TDI, which captures changes from baseline. The BDI and TDI each have three domains: functional impairment, magnitude of task and magnitude of effort, and each domain scored from -3 (major deterioration) to +3 (major improvement), giving an overall score of -9 to +9. A negative score indicates deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.</description>
        <time_frame>Baseline, week 12, week 26</time_frame>
        <population>The number of participants considered for the analysis was from the full analysis set (randomized participants who received at least one dose of study medication). However, for a given time frame, analyzed participants had values at both baseline and the corresponding time frame, i.e. week 12 or week 26.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237</title>
            <description>NVA237 50 µg once daily delivered via a single dose dry powder inhaler</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily delivered via a single dose dry powder inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Transition Dyspnea Index (TDI) Score</title>
          <description>Dyspnea was measured at baseline using the Baseline Dyspnea Index (BDI) and during the treatment period using the TDI, which captures changes from baseline. The BDI and TDI each have three domains: functional impairment, magnitude of task and magnitude of effort, and each domain scored from -3 (major deterioration) to +3 (major improvement), giving an overall score of -9 to +9. A negative score indicates deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.</description>
          <population>The number of participants considered for the analysis was from the full analysis set (randomized participants who received at least one dose of study medication). However, for a given time frame, analyzed participants had values at both baseline and the corresponding time frame, i.e. week 12 or week 26.</population>
          <units>score</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 12 (n=288,141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="0.32"/>
                    <measurement group_id="O2" value="1.6" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 26 (n=284,140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="0.31"/>
                    <measurement group_id="O2" value="2.0" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Rescue Medication Use (Number of Puffs)</title>
        <description>The participant recorded the rescue medication taken in an electronic diary between visits and in the spirometry device during study visits. Daytime and nighttime rescue medication use (number of puffs) over 26 weeks was analyzed.</description>
        <time_frame>Baseline, 26 weeks</time_frame>
        <population>Full Analysis Set: The full analysis set included all randomized participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237</title>
            <description>NVA237 50 µg once daily delivered via a single dose dry powder inhaler</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily delivered via a single dose dry powder inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Rescue Medication Use (Number of Puffs)</title>
          <description>The participant recorded the rescue medication taken in an electronic diary between visits and in the spirometry device during study visits. Daytime and nighttime rescue medication use (number of puffs) over 26 weeks was analyzed.</description>
          <population>Full Analysis Set: The full analysis set included all randomized participants who received at least one dose of study medication.</population>
          <units>Number of puffs</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" spread="0.157"/>
                    <measurement group_id="O2" value="-0.55" spread="0.186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>24h Trough FEV1</title>
        <description>Trough FEV1 was defined as the mean of the post-dose 23 h 15 min and the 23 h 45 min FEV1 values. This was measured using central spirometry according to ATS/ERS standardization. This was analyzed using the same MIXED model as specified for the primary analysis.</description>
        <time_frame>Day 1, Week 26</time_frame>
        <population>The number of participants considered for the analysis was from the full analysis set (randomized participants who received at least one dose of study medication). However, for a given time frame, analyzed participants had values at both baseline and the corresponding time frame, i.e. day 1 or week 26.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237</title>
            <description>NVA237 50 µg once daily delivered via a single dose dry powder inhaler</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily delivered via a single dose dry powder inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>24h Trough FEV1</title>
          <description>Trough FEV1 was defined as the mean of the post-dose 23 h 15 min and the 23 h 45 min FEV1 values. This was measured using central spirometry according to ATS/ERS standardization. This was analyzed using the same MIXED model as specified for the primary analysis.</description>
          <population>The number of participants considered for the analysis was from the full analysis set (randomized participants who received at least one dose of study medication). However, for a given time frame, analyzed participants had values at both baseline and the corresponding time frame, i.e. day 1 or week 26.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=289,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.230" spread="0.0084"/>
                    <measurement group_id="O2" value="1.109" spread="0.0104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=281,143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.195" spread="0.0140"/>
                    <measurement group_id="O2" value="1.059" spread="0.0171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 and Forced Vital Capacity (FVC)</title>
        <description>FEV1 and FVC were measured using central spirometry according to ATS/ERS standardization. Both were analyzed using the same MIXED model as specified for the primary analysis.</description>
        <time_frame>Day 1 at 5, 15, 30 minutes (min) and 1 hour (h) post dose; days 2, 86, 184 at 23 (h) 15 min and 23 h 45 min post dose; days 29, 85, 183 at -45 and -15 min pre-dose and 5, 15, and 30 min post dose</time_frame>
        <population>The number of participants considered for the analysis was from the full analysis set (randomized participants who received at least one dose of study medication). However, for a given time frame, analyzed participants had values at both baseline and the corresponding time frame, e.g. day 1, 5 min; day 1, 15 min, etc..</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237</title>
            <description>NVA237 50 µg once daily delivered via a single dose dry powder inhaler</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily delivered via a single dose dry powder inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 and Forced Vital Capacity (FVC)</title>
          <description>FEV1 and FVC were measured using central spirometry according to ATS/ERS standardization. Both were analyzed using the same MIXED model as specified for the primary analysis.</description>
          <population>The number of participants considered for the analysis was from the full analysis set (randomized participants who received at least one dose of study medication). However, for a given time frame, analyzed participants had values at both baseline and the corresponding time frame, e.g. day 1, 5 min; day 1, 15 min, etc..</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FEV1, day 1, 5 min (n=281,143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.199" spread="0.0060"/>
                    <measurement group_id="O2" value="1.112" spread="0.0072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1, day 1, 15 min (n=277,147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.245" spread="0.0075"/>
                    <measurement group_id="O2" value="1.116" spread="0.0089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1, day 1, 30 min (n=283,145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.265" spread="0.0076"/>
                    <measurement group_id="O2" value="1.111" spread="0.0090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1, day 1, 1 h (n=284,142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.295" spread="0.0079"/>
                    <measurement group_id="O2" value="1.124" spread="0.0096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1, day 2, 23 h 15 min (n=267,137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.228" spread="0.0086"/>
                    <measurement group_id="O2" value="1.101" spread="0.0108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1, day 2, 23 h 45 min min (n=272,140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.230" spread="0.0092"/>
                    <measurement group_id="O2" value="1.107" spread="0.0112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1, day 29, -45 min (n=273,136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.208" spread="0.0114"/>
                    <measurement group_id="O2" value="1.079" spread="0.0144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1, day 29, -15 min (n=280,142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.226" spread="0.0113"/>
                    <measurement group_id="O2" value="1.097" spread="0.0142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1, day 29, 5 min (n=271,136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.240" spread="0.0118"/>
                    <measurement group_id="O2" value="1.097" spread="0.0148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1, day 29, 15 min (n=272,135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.259" spread="0.0117"/>
                    <measurement group_id="O2" value="1.103" spread="0.0147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1, day 29, 30 min (n=279,139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.272" spread="0.0114"/>
                    <measurement group_id="O2" value="1.105" spread="0.0142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1, day 85, -45 min (n=269,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.179" spread="0.0118"/>
                    <measurement group_id="O2" value="1.050" spread="0.0147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1, day 85, -15 min (n=271,136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.190" spread="0.0106"/>
                    <measurement group_id="O2" value="1.052" spread="0.0134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1, day 85, 5 min (n=262,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.229" spread="0.0119"/>
                    <measurement group_id="O2" value="1.059" spread="0.0147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1, day 85, 15 min (n=267,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.246" spread="0.0117"/>
                    <measurement group_id="O2" value="1.061" spread="0.0147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1, day 85, 30 min (n=273,137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.263" spread="0.0129"/>
                    <measurement group_id="O2" value="1.077" spread="0.0156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1, day 85, 1 h (n=274,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.275" spread="0.0125"/>
                    <measurement group_id="O2" value="1.079" spread="0.0154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1, day 86, 23 h 15 min (n=261,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.195" spread="0.0146"/>
                    <measurement group_id="O2" value="1.057" spread="0.0175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1, day 86, 23 h 45 min (n=250,132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.203" spread="0.0138"/>
                    <measurement group_id="O2" value="1.067" spread="0.0163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1, day 183, -45 min (n=262,135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.176" spread="0.0148"/>
                    <measurement group_id="O2" value="1.032" spread="0.0176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1, day 183, - 15 min (n=265,135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.179" spread="0.0130"/>
                    <measurement group_id="O2" value="1.052" spread="0.0165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1, day 183, 5 min (n=262,135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.220" spread="0.0136"/>
                    <measurement group_id="O2" value="1.055" spread="0.0170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1, day 183, 15 min (n=261,140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.233" spread="0.0139"/>
                    <measurement group_id="O2" value="1.070" spread="0.0169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1, day 183, 30 min (n=270,138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.265" spread="0.0134"/>
                    <measurement group_id="O2" value="1.071" spread="0.0170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1, day 183, 1 h (n=263,135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.263" spread="0.0137"/>
                    <measurement group_id="O2" value="1.075" spread="0.0168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1, day 184, 23 h 15 min (n=263,128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.197" spread="0.0154"/>
                    <measurement group_id="O2" value="1.068" spread="0.0188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1, day 184, 23 h 45 min (n=266,132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.196" spread="0.0144"/>
                    <measurement group_id="O2" value="1.058" spread="0.0180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC, day 1, 5 min (n=281,143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.925" spread="0.0184"/>
                    <measurement group_id="O2" value="2.739" spread="0.0220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC, day 1, 15 min (n=277,147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.992" spread="0.0252"/>
                    <measurement group_id="O2" value="2.759" spread="0.0288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC, day 1, 30 min (n=283,145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.041" spread="0.0235"/>
                    <measurement group_id="O2" value="2.761" spread="0.0280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC, day 1, 1 h (n=284,142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.044" spread="0.0240"/>
                    <measurement group_id="O2" value="2.755" spread="0.0286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC, day 2, 23 h 15 min (n=267,137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.953" spread="0.0275"/>
                    <measurement group_id="O2" value="2.716" spread="0.0326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC, day 2, 23 h 45 min (n=272,140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.981" spread="0.0261"/>
                    <measurement group_id="O2" value="2.744" spread="0.0311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC, day 29, -45 min (n=273,136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.908" spread="0.0324"/>
                    <measurement group_id="O2" value="2.690" spread="0.0375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC, day 29, -15 min (n=280,142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.927" spread="0.0312"/>
                    <measurement group_id="O2" value="2.730" spread="0.0371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC, day 29, 5 min (n=271,136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.970" spread="0.0292"/>
                    <measurement group_id="O2" value="2.725" spread="0.0353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC, day 29, 15 min (n=272,135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.993" spread="0.0276"/>
                    <measurement group_id="O2" value="2.751" spread="0.0339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC, day 29, 30 min (n=279,139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.995" spread="0.0287"/>
                    <measurement group_id="O2" value="2.737" spread="0.0341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC, day 85, -45 min (n=269,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.854" spread="0.0321"/>
                    <measurement group_id="O2" value="2.611" spread="0.0385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC, day 85, -15 min (n=271,136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.898" spread="0.0318"/>
                    <measurement group_id="O2" value="2.627" spread="0.0373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC, day 85, 5 min (n=262,130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.927" spread="0.0321"/>
                    <measurement group_id="O2" value="2.633" spread="0.0380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC, day 85, 15 min (n=267,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.954" spread="0.0328"/>
                    <measurement group_id="O2" value="2.647" spread="0.0387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC, day 85, 30 min (n=273,137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.977" spread="0.0330"/>
                    <measurement group_id="O2" value="2.695" spread="0.0383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC, day 85, 1 h (n=274,133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.987" spread="0.0347"/>
                    <measurement group_id="O2" value="2.662" spread="0.0400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC, day 86, 23 h 15 min (n=261,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.908" spread="0.0366"/>
                    <measurement group_id="O2" value="2.612" spread="0.0429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC, day 86, 23 h 45 min (n=250,132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.894" spread="0.0360"/>
                    <measurement group_id="O2" value="2.671" spread="0.0412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC, day 183, -45 min (n=262,135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.858" spread="0.0379"/>
                    <measurement group_id="O2" value="2.604" spread="0.0430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC, day 183, -15 min (n=265,135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.862" spread="0.0359"/>
                    <measurement group_id="O2" value="2.633" spread="0.0415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC, day 183, 5 min (n=262,135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.927" spread="0.0368"/>
                    <measurement group_id="O2" value="2.672" spread="0.0426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC, day 183, 15 min (n=261,140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.957" spread="0.0365"/>
                    <measurement group_id="O2" value="2.679" spread="0.0420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC, day 183, 30 min (n=270,138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.988" spread="0.0366"/>
                    <measurement group_id="O2" value="2.707" spread="0.0428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC, day 183, 1 h (n=263,135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.941" spread="0.0401"/>
                    <measurement group_id="O2" value="2.668" spread="0.0453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC, day 184, 23 h 15 min (n=263,128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.869" spread="0.0386"/>
                    <measurement group_id="O2" value="2.664" spread="0.0452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC, day 184, 23 h 45 min (n=266,132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.894" spread="0.0402"/>
                    <measurement group_id="O2" value="2.647" spread="0.0472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1</title>
        <description>Peak FEV1 was defined as the maximum FEV1 0-4 h post-dose. Peak Fev1 was measured at 45min and 15min pre-dose and up to 4h post dose at day 1, week 12 and week 26, using central spirometry according to ATS/ERS standardization. It was analyzed using the same MIXED model as specified for the primary analysis.</description>
        <time_frame>Day 1, week 12, week 26</time_frame>
        <population>The number of participants considered for the analysis was from a Serial Spirometry subgroup of the full analysis set where N = 134 and 58, respectively. However, analyzed participants had values at both baseline and the corresponding time frame, i.e. day 1, week 12 or week 26.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237</title>
            <description>NVA237 50 µg once daily delivered via a single dose dry powder inhaler</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily delivered via a single dose dry powder inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1</title>
          <description>Peak FEV1 was defined as the maximum FEV1 0-4 h post-dose. Peak Fev1 was measured at 45min and 15min pre-dose and up to 4h post dose at day 1, week 12 and week 26, using central spirometry according to ATS/ERS standardization. It was analyzed using the same MIXED model as specified for the primary analysis.</description>
          <population>The number of participants considered for the analysis was from a Serial Spirometry subgroup of the full analysis set where N = 134 and 58, respectively. However, analyzed participants had values at both baseline and the corresponding time frame, i.e. day 1, week 12 or week 26.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=134,57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.376" spread="0.0119"/>
                    <measurement group_id="O2" value="1.183" spread="0.0146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=125,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.347" spread="0.0207"/>
                    <measurement group_id="O2" value="1.140" spread="0.0245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=124,57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.308" spread="0.0250"/>
                    <measurement group_id="O2" value="1.112" spread="0.0298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Standardized FEV1 Area Under the Curve (AUC(5 Min-4 h)) Post-dose</title>
        <description>The standardized (with respect to time) AUC for FEV1 was calculated between 5 min and 4h post morning dose at day 1, week 12 and week 26. The AUC (5 min-4 h) for FEV1 at each visit was analyzed using the same MIXED model as specified for the primary analysis.</description>
        <time_frame>Day 1, week 12, week 26</time_frame>
        <population>The number of participants considered for the analysis was from a Serial Spirometry subgroup of the full analysis set where N = 134 and 58, respectively. However, analyzed participants had values at both baseline and the corresponding time frame, i.e. day 1, week 12 or week 26.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237</title>
            <description>NVA237 50 µg once daily delivered via a single dose dry powder inhaler</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily delivered via a single dose dry powder inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Standardized FEV1 Area Under the Curve (AUC(5 Min-4 h)) Post-dose</title>
          <description>The standardized (with respect to time) AUC for FEV1 was calculated between 5 min and 4h post morning dose at day 1, week 12 and week 26. The AUC (5 min-4 h) for FEV1 at each visit was analyzed using the same MIXED model as specified for the primary analysis.</description>
          <population>The number of participants considered for the analysis was from a Serial Spirometry subgroup of the full analysis set where N = 134 and 58, respectively. However, analyzed participants had values at both baseline and the corresponding time frame, i.e. day 1, week 12 or week 26.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (n=134,57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.311" spread="0.0122"/>
                    <measurement group_id="O2" value="1.117" spread="0.0142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=125,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.286" spread="0.0204"/>
                    <measurement group_id="O2" value="1.080" spread="0.0241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=124,57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.243" spread="0.0229"/>
                    <measurement group_id="O2" value="1.046" spread="0.0280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Chronic Obstructive Pulmonary Disease (COPD) Symptoms (Cough, Wheezing, Shortness of Breath, Sputum Volume, Sputum Color and Night Time Awakenings)</title>
        <description>In an electronic diary, the participant responded to 6 questions twice daily to report on the degree of symptoms over the past 12 hours of the morning and evening. The questions covered the participant’s degree of overall symptoms, and degrees of individual symptoms of coughing, wheezing, amount of sputum, color of sputum and breathlessness. Each question scored from 0 to 3 where 0 represented no symptom present and 3 represented the worst degree of that symptom. A negative change in symptom score indicates improvement.</description>
        <time_frame>Baseline, 26 weeks</time_frame>
        <population>The number of participants considered for the analysis was from the full analysis set (randomized participants who received at least one dose of study medication). However, for a given symptom category, analyzed participants had both baseline and week 26 values.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237</title>
            <description>NVA237 50 µg once daily delivered via a single dose dry powder inhaler</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily delivered via a single dose dry powder inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chronic Obstructive Pulmonary Disease (COPD) Symptoms (Cough, Wheezing, Shortness of Breath, Sputum Volume, Sputum Color and Night Time Awakenings)</title>
          <description>In an electronic diary, the participant responded to 6 questions twice daily to report on the degree of symptoms over the past 12 hours of the morning and evening. The questions covered the participant’s degree of overall symptoms, and degrees of individual symptoms of coughing, wheezing, amount of sputum, color of sputum and breathlessness. Each question scored from 0 to 3 where 0 represented no symptom present and 3 represented the worst degree of that symptom. A negative change in symptom score indicates improvement.</description>
          <population>The number of participants considered for the analysis was from the full analysis set (randomized participants who received at least one dose of study medication). However, for a given symptom category, analyzed participants had both baseline and week 26 values.</population>
          <units>score</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total symptom (n=296,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.16" spread="0.143"/>
                    <measurement group_id="O2" value="-0.85" spread="0.164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory symptom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="0.033"/>
                    <measurement group_id="O2" value="-0.12" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough symptom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="0.030"/>
                    <measurement group_id="O2" value="-0.20" spread="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wheeze symptom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="0.030"/>
                    <measurement group_id="O2" value="-0.22" spread="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sputum production</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="0.034"/>
                    <measurement group_id="O2" value="-0.11" spread="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sputum color</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.025"/>
                    <measurement group_id="O2" value="-0.10" spread="0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breathless symptom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="0.030"/>
                    <measurement group_id="O2" value="-0.10" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Moderate or Severe COPD Exacerbation</title>
        <description>A COPD exacerbation was defined as a worsening of the following two or more major symptoms for at least 2 consecutive days:1) dyspnea; 2) sputum volume; 3) sputum purulence; or defined as a worsening of any 1 major symptom together with an increase in any 1 of the following minor symptoms for at least 2 consecutive days: 1) sore throat; 2) colds (nasal discharge and/or nasal congestion); 3) fever without other cause; 4) cough; 5) wheeze. COPD exacerbations were recorded in the patient diary and other source documents.</description>
        <time_frame>26 weeks</time_frame>
        <population>Full Analysis Set: The full analysis set included all randomized patients who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237</title>
            <description>NVA237 50 µg once daily delivered via a single dose dry powder inhaler</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily delivered via a single dose dry powder inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Moderate or Severe COPD Exacerbation</title>
          <description>A COPD exacerbation was defined as a worsening of the following two or more major symptoms for at least 2 consecutive days:1) dyspnea; 2) sputum volume; 3) sputum purulence; or defined as a worsening of any 1 major symptom together with an increase in any 1 of the following minor symptoms for at least 2 consecutive days: 1) sore throat; 2) colds (nasal discharge and/or nasal congestion); 3) fever without other cause; 4) cough; 5) wheeze. COPD exacerbations were recorded in the patient diary and other source documents.</description>
          <population>Full Analysis Set: The full analysis set included all randomized patients who received at least one dose of study medication.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median time was not estimable due to the low number of participants with moderate or severe COPD exacerbations.</measurement>
                    <measurement group_id="O2" value="NA">The median time was not estimable due to the low number of participants with moderate or severe COPD exacerbations.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Moderate and Severe COPD Exacerbations</title>
        <description>COPD exacerbations were recorded in the patient diary and other source documents. The rate of COPD exacerbations during the 26 week treatment period was analyzed using a generalized linear model assuming a negative binomial distribution.</description>
        <time_frame>26 weeks</time_frame>
        <population>Full Analysis Set: The full analysis set included all randomized patients who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237</title>
            <description>NVA237 50 µg once daily delivered via a single dose dry powder inhaler</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily delivered via a single dose dry powder inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Moderate and Severe COPD Exacerbations</title>
          <description>COPD exacerbations were recorded in the patient diary and other source documents. The rate of COPD exacerbations during the 26 week treatment period was analyzed using a generalized linear model assuming a negative binomial distribution.</description>
          <population>Full Analysis Set: The full analysis set included all randomized patients who received at least one dose of study medication.</population>
          <units>Number of exacerbations</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.48"/>
                    <measurement group_id="O2" value="0.3" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Total Score of the St George's Respiratory Questionnaire (SGRQ)</title>
        <description>SGRQ is a health related quality of life questionnaire consisting of 51 items in three components: symptoms, activity and impacts. The lowest possible score is zero and the highest possible score is 100. Higher scores correspond to greater impairment in quality of life. The health-related quality of life was measured using SGRQ. It was completed by the participant at the investigators site.</description>
        <time_frame>Week 12, week 26</time_frame>
        <population>The number of participants considered for the analysis was from the full analysis set (randomized participants who received at least one dose of study medication). However, for a given time frame, analyzed participants had values at both baseline and the corresponding time frame, i.e. week 12 or week 26.</population>
        <group_list>
          <group group_id="O1">
            <title>NVA237</title>
            <description>NVA237 50 µg once daily delivered via a single dose dry powder inhaler</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily delivered via a single dose dry powder inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>The Total Score of the St George's Respiratory Questionnaire (SGRQ)</title>
          <description>SGRQ is a health related quality of life questionnaire consisting of 51 items in three components: symptoms, activity and impacts. The lowest possible score is zero and the highest possible score is 100. Higher scores correspond to greater impairment in quality of life. The health-related quality of life was measured using SGRQ. It was completed by the participant at the investigators site.</description>
          <population>The number of participants considered for the analysis was from the full analysis set (randomized participants who received at least one dose of study medication). However, for a given time frame, analyzed participants had values at both baseline and the corresponding time frame, i.e. week 12 or week 26.</population>
          <units>Score</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 12 (n=293,147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.35" spread="1.232"/>
                    <measurement group_id="O2" value="37.39" spread="1.399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 26 (n=288,144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.02" spread="1.480"/>
                    <measurement group_id="O2" value="35.94" spread="1.641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>NVA237</title>
          <description>NVA237 50 µg once daily delivered via a single dose dry powder inhaler</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo once daily delivered via a single dose dry powder inhaler</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Cor pulmonale chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Thalamus haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="305"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

